Gaining Ground in GI Cancers in Denver

Podcast

We traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty.

We recently traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty. Meeting topics spanned the importance of molecular testing in the management of newly diagnosed metastatic colorectal cancer, advances with biomarker-directed therapies and immunotherapies in the relapsed/refractory setting, and the role of tumor sidedness in the treatment of the disease. Experts also highlighted novel approaches being explored in pancreatic cancer, data with immunotherapy in gastric and gastroesophageal junction cancer, and novel investigational agents in hepatocellular carcinoma.

Related Videos
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Michael J. Overman, MD
Manish A. Shah, MD, director, Gastrointestinal Oncology Program, Weill Cornell Medicine; chief, Solid Tumor Service, co-director, Center for Advanced Digestive Disease, NewYork Presbyterian
Katrina S. Pedersen, MD, MS
Efrat Dotan, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.